IPO - Nuwellis, Inc.

Form Type: S-1

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000114036125020878

Filing Summary: Nuwellis, Inc. is conducting an initial public offering (IPO) with the registration of 5,387,931 shares of common stock and pre-funded warrants to purchase shares of common stock. The IPO price is set at $0.928 per share, which is the closing price on Nasdaq on May 23, 2025. The company is also offering Series A Warrants to purchase up to 10,775,862 shares and Series B Warrants to purchase up to 5,387,931 shares, both valid for five years from stockholder approval. The offering includes provisions for pre-funded warrants for investors whose ownership post-offering would exceed 4.99% or 9.99% of the company’s stock. The prospectus outlines that the company may utilize the funds raised for working capital and potential acquisition activity. A 45-day option has been granted to underwriters to purchase additional shares, and the offering will include representative warrants to underwriters as part of their compensation. This registration is filed with the SEC under the Securities Act of 1933, indicating significant developments in the company's capital-raising efforts and its strategy for future growth.

Form Type: DRS

Filing Date: 2025-04-11

Corporate Action: Ipo

Type: New

Accession Number: 000114036125013532

Filing Summary: Nuwellis, Inc. filed a draft registration statement for an initial public offering (IPO) under Form S-1 with the Securities and Exchange Commission on April 11, 2025. The company, based in Eden Prairie, Minnesota, specializes in medical devices for ultrafiltration therapy, primarily the Aquadex SmartFlow system, which targets patients with fluid overload. The registration indicates the intention to sell shares of common stock and common warrants, with pre-funded warrants available to certain purchasers. The prospectus outlines the proposed offering details, including share prices, exercise prices for warrants, and the inability to list the pre-funded warrants or common warrants on any securities exchange. As a smaller reporting company, Nuwellis will benefit from reduced disclosure requirements, which may influence the attractiveness of its common stock in the market and its trading volume. The company anticipates using the proceeds from the offering for working capital and general corporate purposes. It highlights that an investment in its securities involves substantial risk, particularly as it relies heavily on a single product for revenue.